Sanofi SNY introduced that the FDA has accepted for assessment its supplemental biologics license utility (sBLA) in search of approval for its blockbuster inflammatory drug Dupixent (dupilumab) as an add-on therapy of uncontrolled moderate-to-severe bronchial asthma in youngsters aged six to 11 www.nasdaq.com
Sanofi SNY introduced that the FDA has accepted for assessment its supplemental biologics license utility (sBLA) in search of approval for its blockbuster inflammatory drug Dupixent (dupilumab) as an add-on therapy of uncontrolled moderate-to-severe bronchial asthma in youngsters aged six to 11
www.nasdaq.com